References
- Rieder MJ. If children ruled the pharmaceutical industry: The need for
pediatric formulations. Drug News Perspect 2010; 23: 458-64.
- Bideau A. Desjardins B, Pérez Brignoli H (eds). Infant and Child
Mortality in the Past. Claredon Press, Oxford, 1997.
- Kermack W, McKendrick AG, McKinley PL. Death Rates in Great Britain
and Sweden: Some general regularities and their significance.Lancet 1934; 31: 698-703.
- UN Inter-agency Group for Child Mortality Estimation,
https://childmortality.org
- Fleming A. On the antibacterial action of cultures of a penicillium
with special reference to their use in the isolation of B.
influenzae. Br J Exper Path 1929; 10: 226-36.
- Weinshilboum RM. The therapeutic revolution. Clin Pharmacol
Ther 1987; 42: 481-5.
- Domagk G. Eine neue klasse von desinfektionshmittelm. Deutsch
Med Wochenschr 1935; 61: 829-32.
- Tréfouël J, Tréfouël J, Nitti F, Bovet D. Activité du
p-aminophényl-sulfamide sur les infections stretococciques
expérimentales de la souris et du lapin. Cr Scanc Soc Biol1935; 120: 756-8.
- Thomas L. The youngest science: Notes of a medicine-watcher. Viking
Press. New York, 1983.
- O’Leary M, Krailo M, Reaman GH. Progress in childhood cancer: 50 years
of research collaboration, a report from the Children’s Oncology
Group. Semin Oncol 2008; 35: 484-93.
- Connolly CA. Drug Therapy: From ‘Baby Killers’ to Baby Savers,
1906–1933.” In: Children and Drug Safety: Balancing Risk and
Protection in Twentieth-Century America , by Cynthia A Connolly,
Rutgers University Press, New Brunswick, Camden, Newark, New Jersey;
London, 2018, pp. 1–15.
- Wax PM. Elixirs, diluents and the passage of the 1938 Federal Food,
Drug and Cosmetic Act. Ann Intern Med 1995; 122: 456-61.
- Sutherland JM. Fatal cardiovascular collapse of infants receiving
large amounts of chloramphenicol. Am J Dis Child 1959; 97:
761-7.
- Mulhall A, de Louvois J, Hurley R. Chloramphenicol toxicity in
neonates Its incidence and prevention. Br Med J 1983; 287:
1424-6.
- Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental
pharmacology – drug disposition, action and therapy in infants and
children. N Engl J Med 2003; 349: 1157-67.
- Burke EC. Abraham Jacobi, MD: The man and his legacy. Pediatr1998; 101: 309-12.
- Burgio GR. The thalidomide disaster revisited. Eur J Pediatr1981; 136: 229-30.
- Vargesson N. Thalidomide induced teratogenesis: History and
mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140-56.
- McBride WG. Thalidomide and congenital malformations.. Lancet1961; 2: 1358.
- Lenz W. Kindliche missbildungen nach medikameteinnahme wahrend der
graviditat? Dtsch Med Wochensche 1961; 86: 2555-6.
- Kauffman RE. Status of drug approval processes and regulation of
medications for children. Curr Opin Pediatr 1995; 7: 195-8.
- Shirkey HC. Therapeutic orphans J Pediatr 1968; 72: 119-20.
- Kauffman RE. Essential drug for infants and children: North American
perspective. Pediatr 1999; 104 (S3):603-5.
- Committee on Drugs, American Academy of Pediatrics. Use of drugs not
described in the package insert (off-label uses). Pediatr 2002;
110: 181-3.
- Pandolfini C, Bonatii M. A literature review on off-label drug use in
children. Eur J Pediatr 2005; 164: 522-8.
- MacLeod SM. Current environment for drug development, regulation and
use. In: Improving Medicines for Children in Canada. Council of
Canadian Academies, Ottawa, Ontario, 2014.
- Rieder MJ, Matsui D, MacLeod S: Myths and challenges – Drug
utilization by Canadian children. Paed Child Health 2003; 8: 7A-8A
- Khaled LA, Ahmed F, Brogan T et al. Prescription drug use by
one million Canadian children. Paed Child Health 2003; 8
(Supple A), 1-51.
- Lasky T. Estimates of pediatric medication use in the United States:
current abilities and limitations. Clin Ther 2009;31:436-45.
- Turner MA, Lewis S, Hawcutt DB, Field D. Prioritising neonatal
medicines research: UK Medicines for Children Research Network scoping
survey. BMC Pediatr 2009 Aug 12;9:50.
- Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Medication use among
children <12 years of age in the United States: results from
the Slone Survey. Pediatr 2009;124:446-54.
- Clavenna A, Bonati M. Drug prescriptions to outpatient children: a
review of the literature. Eur J Clin Pharmacol 2009;65:749-55.
- Chai G, Governale L, McMahon AW, Trinidad AW Trinidad JP, Staffa J,
Murphy D. Trends of outpatient prescription drug use in US children,
2002-2010. Pediatr 2012 ;130:23-31.
- Rashed AN, Wong ICK, Wilton L, Tomlin S, Neubert A. Drug utilization
patterns in children admitted to a paediatric general medical ward in
five countries. Drugs Real World Outcomes 2015; 2: 397-410.
- Rosli R, Dali AF, Abd Aziz N, Abdullah AH, Ming LC, Manan MM. Drug
utilization on neonatal Wards: A systematic review of observational
Studies. Front Pharmacol 2017; 8:27.
- Martin CB, Hales CM, Gu Q, Ogden CL. Prescription drug use in the
United States, 2015-2016. NCHS Data Brief 2019; 334.
- Swart J, Giancane G, Horneff G et al. Pharmacovigilance in
juvenile idiopathic arthritis patients treated with biologic or
synthetic drugs: Combined data of more than 15,000 patients from
Pharmachild and national registries. Arthritis Res Ther 2018;
20: 285.
- Griesenauer RH, Kinch MS. 2016 in review: FDA approvals of new
molecular entitites. Drug Discov Today 2017; Jul 4. pii:
S1359-6446(17)30129-0.
- Mahmood I. Pharmacokinetic considerations in designing pediatric
studies of proteins, antibiotics and plasma-derived products. Am
J Ther 2016;23:e1043-56.
- Wilson JT. Update on the therapeutic orphan. Pediatr 1999; 104:
585-9.
- Aronson JK, Ferner RE. Unlicensed and off-label uses of medicine:
Definitions and clarification of terminology. Br J Clin
Pharmacol 2017; 83: 2615-25.
- Cohen SN. The pediatric pharmacology research unit (PPRU) network and
its role in meeting pediatric labeling needs. Pediatr 1999;
104: 644-5.
- Institute of Medicine (US) Forum on Drug Discovery, Development, and
Translation. Addressing the Barriers to Pediatric Drug Development:
Workshop Summary. Washington (DC): National Academies Press (US);
2008. 2, Regulatory Framework.
- Wharton GT, Murphy MD, Avant D et al. Impact of pediatric
exclusivity on drug labelling and demonstrations of efficacy.Pediatr 2014; 134: e512-8.
- Penkov D, Tomasi P, Eichler I et al. Pediatric medicine
development: An overview and comparison of regulatory processes in the
European Union and the United States. Ther Inno Regul Sci 2017;
51: 360-71.
- Thomsen MDT. Global pediatric drug development. Curr Ther Res2019; 90: 135-42.
- Moore Hepburn C, Gilpin A, Autmizguine J et al. Improving
paediatric medications: A prescription for Canadian chidren and youth.Paeds Child Health 2019; 24: 333-5.
- Saitou H, Nakatani D, Myoui A, Kubota , Ozono K. Pediatric drug
development in Japan: Current issues and perspectives. Clin
Pediatr Endocrinol 2020; 29: 1-7.
- Committee on Drugs, American Academy of Pediatrics. Off-label use of
drugs in children. Pediatr 2014, 133 563-567.
- Corny J, Lebel D, Bailey B, Bussières JF. Unlicensed and off-label
drug use in children before and after pediatric government incentives.J Pediatr Pharmacol Ther 2015; 20: 316-28.
- Rieder MJ. Size and Taste Matters: Recent Progress in the Development
of Age-Appropriate Medicines for Children. Pharmaceut Med2018; 32:21-30.
- Gerrard SE, Walsh J, Bowers N, Salunka S, Hershenson S. Innovations in
pediatric drug formulations and administration technologies for low
resource settings. Pharmaceutics 2019; 11:
doi:10.3390/pharmaceutics 11100518.
- Thabet Y, Klingmann V, Breitkreutz J. Drug formulation: Standards and
novel strategies for drug administration in pediatics. J Clin
Pharmacol 2018;58 Suppl 10:S26-S35.
- Teixeira T, Kweder SL, Saint-Raymond A. Are the European Medicine
Agency, US Food and Drug Administration, and other international
regulators talking to each other? Clin Pharmacol Ther 2020:
107: 507-13.
- Rieder M, Hawcutt D. Design and conduct of early phase drug studies in
children. Br J Clin Pharmacol 2016;82:1308-1314. PMID: 27353241
- Duffett M, Swinton M, Brouwers M, Meade M, Cook DJ. Advancing
randomized controlled trials in pediatric critical care: The
perspectives of trialists. Pediatr Crit Care Med2018;19:e595-e602.
- Cohen JW, Akshintala S, Kane E, et al. A systematic review of
pediatric Phase I trails in oncology: Toxicity and outcomes in the era
of targeted therapies. Oncologist 2020 Jan 14. doi:
10.1634/theoncologist.2019-0615.
- Collingnon O, Gartner C, Haidich A-B et al. Current statistical
considerations and regulatory perspectives on the planning of
confimatory basket, umbrella and platform trials. Clin Pharmacol
Ther 2020; 107: 1059-67.
- Breckenridge A, Feldschreiber P. Impact of Brexit on UK and EU Drug
Regulation and Patient Access. Clin Pharmacol Ther 2019; 105:
923-5.
- MacLeod SM, Greff M, Knoppert DC, Ito S, Rieder MJ. An international
asset map of clinicians, educators and researchers pursing better
medicine use in children: Initial findings. Clin Pharmacol Ther2017; 101: 274-80.